StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 16 Jun 2026 08:33:03 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research http://www.streetinsider.com/Corporate+News/OPTIMI+Health+adds+1mg+and+2mg+psilocybin+doses+for+clinical+research/26651070.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) announced it has completed production of two microdose psilocybin finished drug products, formulated at 1mg and 2mg, available to qualified, authorized clinical research organizations.</p><p>The products are manufactured at the company's wholly owned GMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment License. Optimi produces the products entirely in-house, from cultivating and harvesting mushrooms to generating a full-spectrum mushroom extract as the active pharmaceutical ingredient, through to encapsulation and packaging for export.</p><p>The two new formulations expand Optimi's existing psilocybin product range, which includes a 5mg capsule currently prescribed for http://www.streetinsider.com/Corporate+News/OPTIMI+Health+adds+1mg+and+2mg+psilocybin+doses+for+clinical+research/26651070.html Tue, 16 Jun 2026 08:33:03 -0400 8BN OPTH OPTHF OPTI OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research http://www.streetinsider.com/Corporate+News/OPTIMI+Health+adds+1mg+and+2mg+psilocybin+doses+for+clinical+research/26651070.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) announced it has completed production of two microdose psilocybin finished drug products, formulated at 1mg and 2mg, available to qualified, authorized clinical research organizations.</p><p>The products are manufactured at the company's wholly owned GMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment License. Optimi produces the products entirely in-house, from cultivating and harvesting mushrooms to generating a full-spectrum mushroom extract as the active pharmaceutical ingredient, through to encapsulation and packaging for export.</p><p>The two new formulations expand Optimi's existing psilocybin product range, which includes a 5mg capsule currently prescribed for http://www.streetinsider.com/Corporate+News/OPTIMI+Health+adds+1mg+and+2mg+psilocybin+doses+for+clinical+research/26651070.html Tue, 16 Jun 2026 08:33:03 -0400 8BN OPTH OPTHF OPTI OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research http://www.streetinsider.com/Corporate+News/OPTIMI+Health+adds+1mg+and+2mg+psilocybin+doses+for+clinical+research/26651070.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) announced it has completed production of two microdose psilocybin finished drug products, formulated at 1mg and 2mg, available to qualified, authorized clinical research organizations.</p><p>The products are manufactured at the company's wholly owned GMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment License. Optimi produces the products entirely in-house, from cultivating and harvesting mushrooms to generating a full-spectrum mushroom extract as the active pharmaceutical ingredient, through to encapsulation and packaging for export.</p><p>The two new formulations expand Optimi's existing psilocybin product range, which includes a 5mg capsule currently prescribed for http://www.streetinsider.com/Corporate+News/OPTIMI+Health+adds+1mg+and+2mg+psilocybin+doses+for+clinical+research/26651070.html Tue, 16 Jun 2026 08:33:03 -0400 8BN OPTH OPTHF OPTI OPTIMI Health adds 1mg and 2mg psilocybin doses for clinical research http://www.streetinsider.com/Corporate+News/OPTIMI+Health+adds+1mg+and+2mg+psilocybin+doses+for+clinical+research/26651070.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) announced it has completed production of two microdose psilocybin finished drug products, formulated at 1mg and 2mg, available to qualified, authorized clinical research organizations.</p><p>The products are manufactured at the company's wholly owned GMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment License. Optimi produces the products entirely in-house, from cultivating and harvesting mushrooms to generating a full-spectrum mushroom extract as the active pharmaceutical ingredient, through to encapsulation and packaging for export.</p><p>The two new formulations expand Optimi's existing psilocybin product range, which includes a 5mg capsule currently prescribed for http://www.streetinsider.com/Corporate+News/OPTIMI+Health+adds+1mg+and+2mg+psilocybin+doses+for+clinical+research/26651070.html Tue, 16 Jun 2026 08:33:03 -0400 8BN OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Press+Releases/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html <p align="center"><em>Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies</em></p> <p align="center"><em>New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme</em></p> <p align="justify">VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=VlQq1qfaWL8yWDpCxfGLBMccy0vvKVRux9yRvg-rQdTRT2JomGf35BZCh8e0q3hs2-_pBFjT9l4KHoh3Kjk1924r1I5DM8jkpGaCs91L42tFNq3PdhFS149VEGKb4Qra" rel="nofollow" target="_blank">Optimi Health Corp.</a> (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "<strong>Company</strong>" or "<strong>Optimi</strong>"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Launches+Standardized+Microdose+Psilocybin+Products+for+Clinical+Research/26651012.html Tue, 16 Jun 2026 08:30:00 -0400 8BN O.53098441 OPTH OPTHF OPTI Form 424B4 Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++424B4++++++Optimi+Health+Corp.++++++++++++++++++/26525130.html si-local-file:///var/storage/secattach/20260520/26525130.html http://www.streetinsider.com/SEC+Filings/Form++424B4++++++Optimi+Health+Corp.++++++++++++++++++/26525130.html Wed, 20 May 2026 08:00:00 -0400 O.53098441 OPTHF OPTI Form 424B4 Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++424B4++++++Optimi+Health+Corp.++++++++++++++++++/26525130.html si-local-file:///var/storage/secattach/20260520/26525130.html http://www.streetinsider.com/SEC+Filings/Form++424B4++++++Optimi+Health+Corp.++++++++++++++++++/26525130.html Wed, 20 May 2026 08:00:00 -0400 O.53098441 OPTHF OPTI Form 424B4 Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++424B4++++++Optimi+Health+Corp.++++++++++++++++++/26525130.html si-local-file:///var/storage/secattach/20260520/26525130.html http://www.streetinsider.com/SEC+Filings/Form++424B4++++++Optimi+Health+Corp.++++++++++++++++++/26525130.html Wed, 20 May 2026 08:00:00 -0400 O.53098441 OPTHF OPTI Form EFFECT Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Optimi+Health+Corp.++++++++++++++++++/26524293.html si-local-file:///var/storage/secattach/20260520/26524293.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Optimi+Health+Corp.++++++++++++++++++/26524293.html Wed, 20 May 2026 06:04:00 -0400 O.53098441 OPTHF OPTI Form EFFECT Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Optimi+Health+Corp.++++++++++++++++++/26524293.html si-local-file:///var/storage/secattach/20260520/26524293.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Optimi+Health+Corp.++++++++++++++++++/26524293.html Wed, 20 May 2026 06:04:00 -0400 O.53098441 OPTHF OPTI Form EFFECT Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Optimi+Health+Corp.++++++++++++++++++/26524293.html si-local-file:///var/storage/secattach/20260520/26524293.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Optimi+Health+Corp.++++++++++++++++++/26524293.html Wed, 20 May 2026 06:04:00 -0400 O.53098441 OPTHF OPTI Form CERT Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++Optimi+Health+Corp.++++++++++++++++++/26522085.html si-local-file:///var/storage/secattach/20260519/26522085.html http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++Optimi+Health+Corp.++++++++++++++++++/26522085.html Tue, 19 May 2026 16:44:00 -0400 O.53098441 OPTHF OPTI Form CERT Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++Optimi+Health+Corp.++++++++++++++++++/26522085.html si-local-file:///var/storage/secattach/20260519/26522085.html http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++Optimi+Health+Corp.++++++++++++++++++/26522085.html Tue, 19 May 2026 16:44:00 -0400 O.53098441 OPTHF OPTI Form CERT Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++Optimi+Health+Corp.++++++++++++++++++/26522085.html si-local-file:///var/storage/secattach/20260519/26522085.html http://www.streetinsider.com/SEC+Filings/Form++CERT+++++++Optimi+Health+Corp.++++++++++++++++++/26522085.html Tue, 19 May 2026 16:44:00 -0400 O.53098441 OPTHF OPTI Form 8-A12B Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++Optimi+Health+Corp.++++++++++++++++++/26518164.html si-local-file:///var/storage/secattach/20260519/26518164.html http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++Optimi+Health+Corp.++++++++++++++++++/26518164.html Tue, 19 May 2026 08:55:00 -0400 O.53098441 OPTHF OPTI Form 8-A12B Optimi Health Corp. http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++Optimi+Health+Corp.++++++++++++++++++/26518164.html si-local-file:///var/storage/secattach/20260519/26518164.html http://www.streetinsider.com/SEC+Filings/Form++8-A12B+++++Optimi+Health+Corp.++++++++++++++++++/26518164.html Tue, 19 May 2026 08:55:00 -0400 O.53098441 OPTHF OPTI